Shots:
- Ascendis Pharma has reported the P-II (New InsiGHTS) trial data assessing TransCon hGH (lonapegsomatropin, QW) vs somatropin (QD) in 49 prepubertal children (1-10yrs.) with Turner syndrome
- At Wk. 52, TransCon hGH showed improved annualized height velocity (AHV) with LS mean AHV of 9.05 vs 9.04 cm/year, irrespective of starting dose, with mean dose of 0.22 mg/kg/week vs 0.29 mg/kg/week for somatropin at 52wks.
- Additionally, TransCon hGH demonstrated a favorable safety & tolerability profile through follow-up of ~143wks., plus it is also being evaluated in a recently-initiated P-III (HighLiGHts) basket trial to support label expansion
Ref: Globenewswire | Image: Ascendis | Press Release
Related News: Ascendis’ Yuviwel (Navepegritide) Receives the US FDA Accelerated Approval for Achondroplasia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
